Hemantane Explained

Width:	175px
Pubchem:	9838302
Chemspiderid:	8014022
Synonyms:	Hymantane; N-Adamant-2-ylhexamethyleneimine; N-(2-Adamantyl)hexamethyleneimine
Iupac Name:	1-(2-adamantyl)azepane
C:	16
H:	27
N:	1
Smiles:	C1CCCN(CC1)C2C3CC4CC(C3)CC2C4
Stdinchi:	1S/C16H27N/c1-2-4-6-17(5-3-1)16-14-8-12-7-13(10-14)11-15(16)9-12/h12-16H,1-11H2
Stdinchikey:	JAROVUWOMYMQCW-UHFFFAOYSA-N

Hemantane, or hymantane, also known as N-(2-adamantyl)hexamethyleneimine, is an experimental antiparkinsonian agent of the adamantane family that was never marketed.^[1] It was developed and studied in Russia.

It has been said to act as a low-affinity non-competitive NMDA receptor antagonist, as a selective MAO-B inhibitor, and as showing various other actions and effects such as modulation of the dopaminergic and serotonergic systems in the striatum.^[2] The drug has also been theorized to be a sigma receptor agonist, which is said to likely be involved in its dopaminergic effects. Analogues of hemantane, such as memantine and amantadine, share some of these actions, like NMDA receptor antagonism, sigma receptor agonism, and dopaminergic modulation.

The drug was first described by 2000.^{[3] [4]}

See also

• Gludantan
• List of Russian drugs

Notes and References

1. Abaimov DA, Kovalev GI . Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease . Neurochemical Journal . 5 . 2 . 2011 . 1819-7124 . 10.1134/S1819712411010028 . 83–91.
2. Fischler PV, Soyka M, Seifritz E, Mutschler J . Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review . Frontiers in Pharmacology . 13 . 927703 . 2022 . 36263121 . 9574013 . 10.3389/fphar.2022.927703 . free .
3. Val'dman EA . [Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration] . Russian . Eksperimental'naia i Klinicheskaia Farmakologiia . 63 . 5 . 3–6 . 2000 . 11109514 .
4. Andiarzhanova EA, Val'dman EA, Kudrin VS, Raevskiĭ KS, Voronina TA . [Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)] . Russian . Eksperimental'naia i Klinicheskaia Farmakologiia . 64 . 6 . 13–16 . 2001 . 11871228 .